MétaCan
Menu
← Back to cohort
Record W2289925905 · doi:10.1161/atvb.34.suppl_1.411

Abstract 411: Effect of Sitagliptin Therapy on Triglyceride-Rich Lipoprotein Kinetics in Patients With Type 2 Diabetes

2014· article· en· W2289925905 on OpenAlexaff
André Tremblay, Benoı̂t Lamarche, Isabelle Kelly, Amélie Charest, Marie‐Claude Lépine, Arnaud Droit, Patrick Couture

Bibliographic record

VenueArteriosclerosis Thrombosis and Vascular Biology · 2014
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsUniversité Laval
Fundersnot available
KeywordsSitagliptinInternal medicineEndocrinologyPostprandialMedicineType 2 diabetesApolipoprotein BIncretinTriglyceridePlaceboSitagliptin PhosphateInsulinVery low-density lipoproteinCrossover studyCholesterolDiabetes mellitusLipoprotein

Abstract

fetched live from OpenAlex

Postprandial hyperlipemia is a key metabolic feature of insulin-resistant states and an important risk factor for cardiovascular disease, due to the accumulation of atherogenic triglyceride (TG)-rich lipoproteins (TRL) from both hepatic and intestinal origin. Sitagliptin is a selective inhibitor of dipeptidyl peptidase-4 that has been shown to reduce fasting and postprandial glucose levels in patients with type 2 diabetes (T2D) presumably through incretin hormone-mediated improvements in islet function. The objective of the present study was to investigate the effects of sitagliptin therapy on the kinetics of TRL apolipoprotein (apo) B-48, VLDL apoB-100, apoE and apoC-III in patients with type 2 diabetes. Twenty two subjects with T2D (18 men and 4 postmenopausal women, mean age of 58.2±3.8 y) were recruited in this double-blind crossover study using sitagliptin 100 mg/d or placebo for a 6-week period each, with a 4-week washout period between the two phases. At the end of each phase of treatment, the in vivo kinetics of the different apolipoproteins were assessed using a primed-constant infusion of L-[5,5,5-D3]leucine for 12 h with the participants in a constantly fed state. Sitagliptin therapy vs. placebo significantly reduced concentrations of fasting plasma TG (-15.4%, 0.03), apoB-48 (-16.3%, P=0.03), free fatty acids (-9.5%, P= 0.04), HbA1C (placebo: 7.0%±0.8 vs sitagliptin: 6.6%±0.7, P<0.0001), and plasma glucose (-13.5%, P=0.001) without any significant effect on insulin level. Treatment with sitagliptin significantly reduced the pool size of TRL apoB-48 by -20.8% (P=0.03), due to a reduction in the production rate of these particles (-16.0%, P=0.03). VLDL apoB-100 pool size was also significantly decreased by sitagliptin therapy (-9.3%, P=0.03), mainly due to a reduction in the hepatic secretion of these lipoproteins (-9.2%, P=0.06). Finally, sitagliptin treatment had no effect on VLDL apoC-III and apoE levels, but reduced both fractional catabolic and production rates of VLDL apoE (-10.6%, P=0.05 and -12.7%, P=0.04). In conclusion, treatment with sitagliptin for 6 weeks reduces TG-rich apoB-containing lipoproteins levels through a reduction in the synthesis of these particles in patients with T2D.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.238
Teacher spread0.226 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueArteriosclerosis Thrombosis and Vascular Biology→Same topicDiabetes Treatment and Management→French-language works237,207→